The Federal Trade Commission charged that the developer of the fertility app Premom deceived users by sharing their sensitive personal information with third parties, including two China-based firms, disclosed users’ sensitive health data to AppsFlyer and Google, and failed to notify consumers…
Source: www.ftc.gov – Read more
Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused
